newsfilter
← Latest News
SoftBank Vision Fund·

Variant Bio: Genomic discovery on the road less traveled

Summary

  • Variant Bio, a Seattle-based biotech company with 40 employees, uses genomics & advanced analytics to develop therapeutics for underrepresented populations.
  • The company focuses on unique datasets from isolated Indigenous groups in locations like Polynesia, South Africa, & Madagascar to discover novel drug targets often missed by Big Pharma.
  • Unlike traditional studies relying on European ancestry data, Variant Bio leverages population bottlenecks & genetic diversity to identify specific disease mechanisms.
  • The firm has developed potential drug candidates VB-8, VB-11, & VB-12 targeting fibrosis, lupus, & muscle wasting based on its proprietary research.
  • Variant Bio's AI-powered analytics platform, VB-Inference, is being licensed to partners such as Novo Nordisk for up to $50 million to identify disease-related genetic targets.
  • The company prioritizes ethical collaboration through a benefit-sharing model that distributes over $1 million to communities & commits 4% of future revenue to participants.
  • CEO Andrew Farnum & Co-founder Stephane Castel emphasize that high-quality, differentiated data is critical for accelerating drug discovery & solving unmet medical needs.
  • Variant Bio aims to make medicines affordable for the communities whose data drives discoveries via its Affordable Medicines Pledge.
  • The startup demonstrates agility by pivoting from solely developing drugs to monetizing its analytics platform when external value is recognized.
  • Challenges in remote fieldwork include logistical issues like lack of electricity, difficult terrain, & political unrest, yet the team maintains rigorous data collection standards.

Learn how Variant Bio leverages diverse genetic populations and genomic data to unlock new drug targets and advance precision medicine research.

Keywords
Strategy